Johnson & Johnson said it recorded US$766 million in sales of the shot in the first nine months of 2021, and would need sales to triple in the fourth quarter to meet its target.
Johnson & Johnson eyes US$2.5B in COVID-19 vaccine sales despite Q3 slide
